BACKGROUND: Cocaine abuse and dependence continue to be widespread. Currently, there are no pharmacotherapies shown to be effective in the treatment of cocaine dependence. METHODS: A 33-week outpatient clinical trial of fluoxetine (60 mg/day, po) for cocaine dependence that incorporated abstinence-contingent voucher incentives was conducted. Participants (N = 145) were both cocaine and opioid dependent and treated withmethadone. A stratified randomization procedure assigned subjects to one of four conditions: fluoxetine plus voucher incentives (FV), placebo plus voucher incentives (PV), fluoxetine without vouchers (F), and placebo without vouchers (P). Dosing of fluoxetine/placebo was double blind. Primary outcomes were treatment retention and cocaine use based on thrice-weekly urine testing. RESULTS: The PV group had the longest treatment retention (M = 165 days) and lowest probability of cocaine use. The adjusted predicted probabilities of cocaine use were 65% in the P group, 60% in the F group, 56% in the FV group, and 31% in the PV group. CONCLUSIONS:Fluoxetine was not efficacious in reducing cocaine use in patients dually dependent on cocaine and opioids.
RCT Entities:
BACKGROUND:Cocaine abuse and dependence continue to be widespread. Currently, there are no pharmacotherapies shown to be effective in the treatment of cocaine dependence. METHODS: A 33-week outpatient clinical trial of fluoxetine (60 mg/day, po) for cocaine dependence that incorporated abstinence-contingent voucher incentives was conducted. Participants (N = 145) were both cocaine and opioid dependent and treated with methadone. A stratified randomization procedure assigned subjects to one of four conditions: fluoxetine plus voucher incentives (FV), placebo plus voucher incentives (PV), fluoxetine without vouchers (F), and placebo without vouchers (P). Dosing of fluoxetine/placebo was double blind. Primary outcomes were treatment retention and cocaine use based on thrice-weekly urine testing. RESULTS: The PV group had the longest treatment retention (M = 165 days) and lowest probability of cocaine use. The adjusted predicted probabilities of cocaine use were 65% in the P group, 60% in the F group, 56% in the FV group, and 31% in the PV group. CONCLUSIONS:Fluoxetine was not efficacious in reducing cocaine use in patients dually dependent on cocaine and opioids.
Authors: S T Higgins; D D Delaney; A J Budney; W K Bickel; J R Hughes; F Foerg; J W Fenwick Journal: Am J Psychiatry Date: 1991-09 Impact factor: 18.112
Authors: Eileen K Sawyer; Jiyoung Mun; Jonathon A Nye; Heather L Kimmel; Ronald J Voll; Jeffrey S Stehouwer; Kenner C Rice; Mark M Goodman; Leonard L Howell Journal: Neuropsychopharmacology Date: 2012-03-21 Impact factor: 7.853
Authors: Michael J Mancino; Janette McGaugh; Mohit P Chopra; Joseph B Guise; Christopher Cargile; D Keith Williams; Jeff Thostenson; Thomas R Kosten; Nichole Sanders; Alison Oliveto Journal: J Clin Psychopharmacol Date: 2014-04 Impact factor: 3.153
Authors: Maryam Bashiri; Michael J Mancino; Virginia A Stanick; Jeff Thostenson; Thomas R Kosten; Alison H Oliveto Journal: Am J Addict Date: 2017-11-08
Authors: Sharon L Walsh; Lisa S Middleton; Conrad J Wong; Paul A Nuzzo; Charles L Campbell; Craig R Rush; Michelle R Lofwall Journal: Drug Alcohol Depend Date: 2012-11-28 Impact factor: 4.492
Authors: Shijing Liu; Scott D Lane; Joy M Schmitz; Kathryn A Cunningham; Vineeth P John; F Gerard Moeller Journal: J Psychopharmacol Date: 2013-06-12 Impact factor: 4.153
Authors: Danielle R Davis; Allison N Kurti; Joan M Skelly; Ryan Redner; Thomas J White; Stephen T Higgins Journal: Prev Med Date: 2016-08-08 Impact factor: 4.018